Advertisement

The Cell Cycle pp 311-317 | Cite as

The Two Amino Terminal Transforming Functions of the SV40 Large T-Antigen are Required to Overcome P53 Mediated Growth Arrest

  • Robin S. Quartin
  • Arnold J. Levine
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)

Abstract

About 60% of cancers from humans contain mutations at the p53 locus1,2. Most commonly, there is a missense mutation in one of the p53 alleles and a loss of the second allele resulting in a reduction to homozygosity of the mutant gene3. Thus p53 behaves like a tumor suppressor gene4 where a loss of function (recessive to wild-type) enhances the probability of cancerous growth. Returning the wild-type p53 gene into cells that are being transformed by an oncogene5 or are already transformed6 blocks the transformation process and, when p53 is expressed at high levels, inhibits cell division of transformed cells. Cells transformed with a temperature sensitive p53 mutant replicate at 37–39°C, where the p53 protein is in a mutant conformation, but fail to grow at 32°C, where the p53 protein is acting as a wild type tumor suppressor1–8. The wild-type p53 protein blocks progression through the cell cycle in G1 7,8. Thus, the wild-type protein can, under certain circumstances9, regulate progression of cells through the cell cycle while mutant p53 proteins fail to do this. The wild-type p53 protein, but not the mutant protein, can act as a transcription factor10–12 and so it is tempting to speculate that p53-mediated transcription of a set of genes can block progression through the cell cycle in the G1 phase of the cycle.

Keywords

Simian Virus Large Tumor Antigen Primary Mouse Embryo Fibroblast Mutant Conformation Regulate Cell Cycle Events15 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. Hollstein, D. Sidransky, B. Vogelstein, and C.C. Harris, p53 mutations in human cancers, Science 253: 49 (1991).PubMedCrossRefGoogle Scholar
  2. 2.
    A.J. Levine, J. Momand, and C.A. Finlay, The p53 tumor suppressor gene, Nature 351: 453 (1991).PubMedCrossRefGoogle Scholar
  3. 3.
    S.J. Baker, A.C. Preisinger, J.M. Jessup, C. Paraskeva, S. Markowitz, J.K. Willson, S. Hamilton, and B. Vogelstein, p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis, Cancer Res. 50: 7717 (1992).Google Scholar
  4. 4.
    L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours, Nature 356215 (1992).Google Scholar
  5. 5.
    C.A. Finlay, P.W. Hinds, and A.J. Levine, The p53 proto-oncogene can act as a suppressor of transformation, Cell 57: 1083 (1989).PubMedCrossRefGoogle Scholar
  6. 6.
    W.E. Mercer, M. In, G. J. Sauve, E. Appella, S.J. Ullrich, and J.W. Romano, Wild-type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogen 5: 973 (1990).Google Scholar
  7. 7.
    D. Michalovitz, O. Halevy, and M. Oren, Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53, Cell 62: 671 (1990).Google Scholar
  8. 8.
    J. Martinez, I. Georgoff, J. Martinez, and A.J. Levine, Cellular localization and cell cycle regulation by a temperature sensitive p53 protein, Genes & Develop. 5: 151 (1991).Google Scholar
  9. 9.
    M.B. Kastan, O.Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig, Participation of p53 protein in the cellular response to DNA damage, Cancer Res. 51: 6304 (1991).PubMedGoogle Scholar
  10. 10.
    G.E. Farmer, J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives, Wild-type p53 activates transcription in vitro, Nature 358: 83 (1992).PubMedCrossRefGoogle Scholar
  11. 11.
    S. Kern, J.A. Pietenpol, S. Thiagalingam, A. Seymour, K. Kinsler, and B. Vogelstein, Oncogenic forms of p53 inhibit p53-regulated gene expression, Science 256: 827 (1992).PubMedCrossRefGoogle Scholar
  12. 12.
    G.P. Zambetti, J. Bargonetti, K. Walker, C. Prives, and A.J. Levine, Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element, Genes & Develop. 6: 1143 (1992).CrossRefGoogle Scholar
  13. 13.
    D.I.H. Linzer, and A.J. Levine, Characterization of a 54K dalton cellular SV40 tumor antigen in SV40 transformed cells, Ce1117: 43 (1979).Google Scholar
  14. 14.
    D.P. Lane, and L.V. Crawford, T antigen is bound to a host protein in SV40-transformed cells, Nature 278: 261 (1979).Google Scholar
  15. 15.
    M.B. Ewen, J.W. Ludlow, E. Marsilio, J.A. DeCaprio, R.C. Millikan, S.H. Cheng, E. Paucha, and D.M. Livingston, An N-terminal transformation-governingg sequence of SV40 large T antigen contributes to the binding of both p110Rb and a second cellular protein, p120, Cell 58: 257 (1989).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Srinivasan, K.W. Peden, and J.M. Pipas, The large tumor antigen of Simian Virus 40 encodes at least two distinct transforming functions, J. Varol. 63 (12): 5459 (1989).Google Scholar
  17. 17.
    R.L. Brinster, H.Y. Chen, A. Messing, T. van Dyke, A.J. Levine, and R. Palmfiter, Transgenic mice harboring SV40 T antigen genes develop characteristic brain tumors, Cell 37: 367 (1984).PubMedCrossRefGoogle Scholar
  18. 18.
    S. Chen, and E. Paucha, Identification of a region of simian virus 40 large tumor antigen required for cell transformation, J. Varol. 64: 3350 (1990).Google Scholar
  19. 19.
    T.D. Kierstead, and M.J. Tevethia, Association of p53 binding and immortalization of primary C57B1/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J. Varol. 67: 1817 (1993).Google Scholar
  20. 20.
    J.-Y. Lin, and D.T. Simmons, The ability of large T-antigen to complex with p53 is necessary for the increased life span and partial transformation of human cells by SV40, J. Varol. 65: 6447 (1991).Google Scholar
  21. 21.
    L. Sompayrac, and K.J. Danna, A new SV40 mutant that encodes a small fragment of T antigen transforms established rat and mouse cells, Virology 163: 391 (1988).Google Scholar
  22. 22.
    L. Sompayrac, and K.J. Danna, The amino-terminal 147 amino acids of SV40 large T antigen transform secondary rat embryo fibroblasts, Virology 181: 412 (1991).PubMedCrossRefGoogle Scholar
  23. 23.
    M.J. Tevethia, J.M. Pipas, T.D. Kierstead, and C. Cole, Requirements for immortalization of primary mouse embryo fibroblasts probed with mutants bearing deletions in the 3′ end of SV40 gene A, Virology 162: 76 (1988).PubMedCrossRefGoogle Scholar
  24. 24.
    J. Zhu, P.W. Rice, L. Gorsch, M. Abate, and C.N. Cole, Transformation of a continuous rat embryo fibroblast cell line requires three separate domains of simian virus 40 large T antigen, J. Varol. 66: 2780 (1992).Google Scholar
  25. 25.
    J.Y. Zhu, M. Abate, P.W. Rice, and C.N. Cole, The ability of simian virus 40 large T antigen to immortalize primary mouse embryo fibroblasts cosegregates with its ability to bind to p53, J. Varol. 65: 6871 (1991).Google Scholar
  26. 26.
    P. Yaciuk, M.C. Carter, J.M. Pipas, and E. Moran, SV40 large T-antigen expresses a biological activity complementary to p300-associated transforming function of the adenovirus E1A gene products, Mol. Cell. Biol. 11: 2116 (1991).PubMedGoogle Scholar
  27. 27.
    P. Yaciuk, and E. Moran, Analysis with specific polyclonal antiserum indicates that the E1A-associated 300 KDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification, Mol. Cell. Biol. 11: 5389 (1991).PubMedGoogle Scholar
  28. 28.
    N. Dyson, and E. Harlow, Adenovirus E1A targets key regulators of cell proliferation, in: “Cancer Surveys,” A.J. Levine, ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1992).Google Scholar
  29. 29.
    J.A. Mietz, T. Unger, J.M. Huibregtse, and P.M. Howley, The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein, EMBO J. 11: 5013 (1992).PubMedGoogle Scholar
  30. 30.
    P.W. Hinds, C.A. Finlay, and A.J. Levine, Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation, J. Varol. 63: 739 (1989).Google Scholar
  31. 31.
    J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine, The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation, Cell 69: 1237 (1992).PubMedCrossRefGoogle Scholar
  32. 32.
    D. Dittmer, S. Pati, G. Zambetti, S. Chu, A.K. Teresky, M. Moore, C. Finlay, and A.J. Levine, p53 gain of function mutations, Nature Gen. 4: 42 (1993).CrossRefGoogle Scholar
  33. 33.
    G.P. Zambetti, D. Olson, M. Labow, and A.J. Levine, A mutant p53 protein is required for the maintenance of the transformed cell phenotype in p53 plus ras transformed cells, Proc. Natl. Acad. Sci. USA 89: 3952 (1992).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Robin S. Quartin
    • 1
  • Arnold J. Levine
    • 1
  1. 1.Department of Molecular BiologyPrinceton UniversityPrincetonUSA

Personalised recommendations